Hormones, Genes, and Cancer

[1]  Yoon Mi Shin,et al.  Successful Hemostasis with Recombinant Activated Factor VII in a Patient with Massive Hepatic Subcapsular Hematoma , 2009, Case Reports in Gastroenterology.

[2]  Manuel Hidalgo,et al.  Development of matrix metalloproteinase inhibitors in cancer therapy. , 2002, Hematology/oncology clinics of North America.

[3]  Y. Murata,et al.  Ligands for the Peroxisomal Proliferator-Activated Receptor γ and the Retinoid X Receptor Inhibit Aromatase Cytochrome P450 (CYP19) Expression Mediated by Promoter II in Human Breast Adipose. , 2002, Endocrinology.

[4]  Jiong Zhou,et al.  Liver Receptor Homologue-1 (LRH-1) Regulates Expression of Aromatase in Preadipocytes* , 2002, The Journal of Biological Chemistry.

[5]  V. Jordan,et al.  Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention. , 2002, Trends in molecular medicine.

[6]  A. M. Lindsey,et al.  Postmenopausal Survivors of Breast Cancer at Risk for Osteoporosis: Nutritional Intake and Body Size , 2002, Cancer nursing.

[7]  S. Bulun,et al.  Tissue‐Specific Estrogen Biosynthesis and Metabolism , 2001, Annals of the New York Academy of Sciences.

[8]  D. Bentrem,et al.  Effects of the new selective estrogen receptor modulator LY353381.HCl (Arzoxifene) on human endometrial cancer growth in athymic mice. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  P. Munster,et al.  Tamoxifen vs the aromatase inhibitors: news from San Antonio, 2001. , 2001, Cancer control : journal of the Moffitt Cancer Center.

[10]  S. Bulun,et al.  A highly complex organization of the regulatory region of the human CYP19 (aromatase) gene revealed by the Human Genome Project. , 2001, The Journal of clinical endocrinology and metabolism.

[11]  P. Kantoff,et al.  Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. , 2001, The New England journal of medicine.

[12]  D. Bentrem,et al.  Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenografts. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  V. Jordan,et al.  Selective estrogen receptor modulation: a personal perspective. , 2001, Cancer research.

[14]  S. Steinberg,et al.  A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  P. Björntorp,et al.  Polymorphisms of the Androgen Receptor Gene and the Estrogen Receptor β Gene Are Associated with Androgen Levels in Women1 , 2001 .

[16]  V. Jordan,et al.  Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex. , 2001, Cancer research.

[17]  C. Logothetis,et al.  Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  Chris P. Miller,et al.  Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens. , 2001, Journal of medicinal chemistry.

[19]  C. Hudis,et al.  Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Banerjee.  Genasense (Genta Inc). , 2001, Current opinion in investigational drugs.

[21]  S. Bulun,et al.  Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta. , 2001, Cancer research.

[22]  R. Barbieri,et al.  Reproductive Hormones, Cancers, and Conditions in Relation to a Common Genetic Variant of Luteinizing Hormone , 2001 .

[23]  Shiuan Chen,et al.  Down-regulation of promoter 1.3 activity of the human aromatase gene in breast tissue by zinc-finger protein, snail (SnaH). , 2001, Cancer research.

[24]  K. Lunetta,et al.  Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer. , 2000, Cancer research.

[25]  T. Saibara,et al.  Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. , 2000, Oncology reports.

[26]  J. Roth,et al.  Prostate cancer radiosensitization in vivo with adenovirus-mediated p53 gene therapy. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  D. Bentrem,et al.  Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. , 2000, Cancer research.

[28]  P. Brown.  Ongoing trials with matrix metalloproteinase inhibitors , 2000, Expert opinion on investigational drugs.

[29]  J. Eastham,et al.  Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer. , 2000, The Journal of urology.

[30]  D. Edwards,et al.  Progesterone receptor isoform A but not B is expressed in endometriosis. , 2000, The Journal of clinical endocrinology and metabolism.

[31]  A. Zeleniuch‐Jacquotte,et al.  Genetic variant of luteinizing hormone and risk of breast cancer in older women. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[32]  S. Davis,et al.  The Role of Local Estrogen Biosynthesis in Males and Females , 2000, Trends in Endocrinology & Metabolism.

[33]  T. Saibara,et al.  Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice. , 2000, The Journal of clinical investigation.

[34]  D. Cunningham,et al.  Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  T. Hasan,et al.  Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model , 2000, The Prostate.

[36]  H. Glatt,et al.  Association between functional genetic polymorphisms of human sulfotransferases 1A1 and 1A2. , 2000, Pharmacogenetics.

[37]  D. Zhou,et al.  Identification and characterization of a cAMP-responsive element in the region upstream from promoter 1.3 of the human aromatase gene. , 1999, Archives of biochemistry and biophysics.

[38]  M. King,et al.  Single nucleotide polymorphisms (SNPs) in the estrogen receptor gene and breast cancer susceptibility , 1999, The Journal of Steroid Biochemistry and Molecular Biology.

[39]  J Benichou,et al.  Validation studies for models projecting the risk of invasive and total breast cancer incidence. , 1999, Journal of the National Cancer Institute.

[40]  O. Olopade,et al.  Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. , 1999, Journal of the National Cancer Institute.

[41]  C. Albanese,et al.  Activator protein-2 mediates transcriptional activation of the CYP11A1 gene by interaction with Sp1 rather than binding to DNA. , 1999, Molecular endocrinology.

[42]  W. Boon,et al.  Impairment of spermatogenesis in mice lacking a functional aromatase (cyp 19) gene. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[43]  M. Poutanen,et al.  Characterization of molecular and catalytic properties of intact and truncated human 17beta-hydroxysteroid dehydrogenase type 2 enzymes: intracellular localization of the wild-type enzyme in the endoplasmic reticulum. , 1999, Endocrinology.

[44]  S. Davis,et al.  Local estrogen biosynthesis in males and females. , 1999, Endocrine-related cancer.

[45]  Charles D. McDermott,et al.  Broad Antitumor and Antiangiogenic Activities of AG3340, a Potent and Selective MMP Inhibitor Undergoing Advanced Oncology Clinical Trials , 1999, Annals of the New York Academy of Sciences.

[46]  P. D. de Jong,et al.  Transcription factors Sp1 and AP-2 mediate induction of acid sphingomyelinase during monocytic differentiation. , 1999, Journal of lipid research.

[47]  N. Çine,et al.  Role of the mutations Trp8 => Arg and Ile15 => Thr of the human luteinizing hormone beta-subunit in women with polycystic ovary syndrome. , 1999, Fertility and sterility.

[48]  D. Ghosh,et al.  Structure of the ternary complex of human 17beta-hydroxysteroid dehydrogenase type 1 with 3-hydroxyestra-1,3,5,7-tetraen-17-one (equilin) and NADP+. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[49]  D. Ross,et al.  Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. , 1999, Pharmacogenetics.

[50]  R. N. Macsween,et al.  Cirrhosis with steatohepatitis after adjuvant tamoxifen , 1999, The Lancet.

[51]  J. Gustafsson,et al.  Generation and reproductive phenotypes of mice lacking estrogen receptor beta. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[52]  N. Harada,et al.  Disruption of sexual behavior in male aromatase-deficient mice lacking exons 1 and 2 of the cyp19 gene. , 1998, Biochemical and biophysical research communications.

[53]  B. Bonanni,et al.  Biologic activity of tamoxifen at low doses in healthy women. , 1998, Journal of the National Cancer Institute.

[54]  C. Turner,et al.  LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo. , 1998, The Journal of pharmacology and experimental therapeutics.

[55]  S. Easteal,et al.  Determination of a common genetic variant of luteinizing hormone using DNA hybridization and immunoassays , 1998, Clinical endocrinology.

[56]  D. Grant,et al.  NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. , 1998, Pharmacogenetics.

[57]  P. Boyle,et al.  Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women , 1998, The Lancet.

[58]  T. Powles,et al.  Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial , 1998, The Lancet.

[59]  D. Thompson,et al.  Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. , 1998, Journal of medicinal chemistry.

[60]  A. Berchuck,et al.  Progesterone receptor gene polymorphism and risk for breast and ovarian cancer. , 1998, British Journal of Cancer.

[61]  E. Simpson,et al.  Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[62]  S. Davis,et al.  Why do the clinical sequelae of estrogen deficiency affect women more than men? , 1998, The Journal of clinical endocrinology and metabolism.

[63]  R. Nagle,et al.  Synthetic matrix metalloproteinase inhibitor, BB‐94, inhibits the invasion of neoplastic human prostate cells in a mouse model , 1998, The Prostate.

[64]  P B Sigler,et al.  Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[65]  L. Kuller,et al.  Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. , 1998, JAMA.

[66]  M. Pearse,et al.  The Human ICAM-2 Promoter is Endothelial Cell-specific in Vitro and in Vivo and Contains Critical Sp1 and GATA Binding Sites* , 1998, The Journal of Biological Chemistry.

[67]  C. Christiansen,et al.  EFFECTS OF RALOXIFENE ON BONE MINERAL DENSITY, SERUM CHOLESTEROL CONCENTRATIONS, AND UTERINE ENDOMETRIUM IN POSTMENOPAUSAL WOMEN , 1998 .

[68]  G. Suske,et al.  Combinatorial Action of HNF3 and Sp Family Transcription Factors in the Activation of the Rabbit Uteroglobin/CC10 Promoter* , 1998, The Journal of Biological Chemistry.

[69]  J. Fontecilla-Camps,et al.  Unusual Charge Stabilization of NADP+ in 17β-Hydroxysteroid Dehydrogenase* , 1998, The Journal of Biological Chemistry.

[70]  V. Paralkar,et al.  Effects of CP-336,156, a New, Nonsteroidal Estrogen Agonist/Antagonist, on Bone, Serum Cholesterol, Uterus, and Body Composition in Rat Models. , 1998, Endocrinology.

[71]  S. Bulun,et al.  Multiple splicing events involved in regulation of human aromatase expression by a novel promoter, I.6. , 1998, Endocrinology.

[72]  B. Groner,et al.  Characterization of Stat5a and Stat5b Homodimers and Heterodimers and Their Association with the Glucocortiocoid Receptor in Mammary Cells , 1998, Molecular and Cellular Biology.

[73]  G. Giles,et al.  Estrogen receptor polymorphism at codon 325 and risk of breast cancer in women before age forty. , 1998, Journal of the National Cancer Institute.

[74]  J Isola,et al.  Molecular cytogenetics of primary breast cancer by CGH , 1998, Genes, chromosomes & cancer.

[75]  M. Anthony,et al.  Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. , 1998, The Journal of clinical endocrinology and metabolism.

[76]  M. McManus,et al.  Structural and functional characterisation of human sulfotransferases. , 1998, Chemico-biological interactions.

[77]  S. Rodenhuis,et al.  Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. , 1998, Journal of the National Cancer Institute.

[78]  Hajime Orimo,et al.  Isolation and radiation hybrid mapping of dinucleotide repeat polymorphism at the human estrogen receptor β locus , 1998, Journal of Human Genetics.

[79]  M. Poutanen,et al.  Growth factors and phorbol-12-myristate-13-acetate modulate the follicle-stimulating hormone- and cyclic adenosine-3′,5′-monophosphate-dependent regulation of 17β-hydroxysteroid dehydrogenase type 1 expression in rat granulosa cells , 1997, Molecular and Cellular Endocrinology.

[80]  C. D. Jones,et al.  Molecular determinants of tissue selectivity in estrogen receptor modulators. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[81]  W. Huster,et al.  Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. , 1997, American journal of obstetrics and gynecology.

[82]  E. Simpson,et al.  A CRE-like sequence that binds CREB and contributes to cAMP-dependent regulation of the proximal promoter of the human aromatase P450 (CYP19) gene , 1997, Molecular and Cellular Endocrinology.

[83]  B. Spiegelman,et al.  PPAR gamma and the molecular control of adipogenesis. , 1997, The Journal of endocrinology.

[84]  R. Heaney,et al.  Raloxifene and estrogen: comparative bone-remodeling kinetics. , 1997, The Journal of clinical endocrinology and metabolism.

[85]  T. Godfrey,et al.  Allelic imbalance mapping of chromosome 16 shows two regions of common deletion in prostate adenocarcinoma. , 1997, Cancer genetics and cytogenetics.

[86]  C. Christiansen,et al.  Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. , 1997, Circulation.

[87]  T. Willson,et al.  Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. , 1997, Endocrinology.

[88]  M. Poutanen,et al.  Loss of heterozygosity at 16q24.1-q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer. , 1997, Cancer research.

[89]  J. Goméz,et al.  Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. , 1997, The Journal of clinical endocrinology and metabolism.

[90]  R. Vihko,et al.  The Proximal Promoter Region of the Gene Encoding Human 17β-Hydroxysteroid Dehydrogenase Type 1 Contains GATA, AP-2, and Sp1 Response Elements: Analysis of Promoter Function in Choriocarcinoma Cells. , 1997, Endocrinology.

[91]  J. Simard,et al.  (S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen. , 1997, Journal of medicinal chemistry.

[92]  Shiuan Chen,et al.  Gene regulation studies of aromatase expression in breast cancer and adipose stromal cells , 1997, The Journal of Steroid Biochemistry and Molecular Biology.

[93]  N. Harada.  Aberrant expression of aromatase in breast cancer tissues , 1997, The Journal of Steroid Biochemistry and Molecular Biology.

[94]  B. Katzenellenbogen,et al.  The quinone reductase gene: a unique estrogen receptor-regulated gene that is activated by antiestrogens. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[95]  H W Cole,et al.  Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene. , 1997, Journal of medicinal chemistry.

[96]  C. Croce,et al.  Bcl2 is the guardian of microtubule integrity. , 1997, Cancer research.

[97]  A. Sahin,et al.  Deletion map of chromosome 16q in ductal carcinoma in situ of the breast: refining a putative tumor suppressor gene region. , 1996, Cancer research.

[98]  M. Emi,et al.  Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers , 1996, Genes, chromosomes & cancer.

[99]  C. Mendelson,et al.  Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. , 1996, Endocrinology.

[100]  R. Weinshilboum,et al.  Human dehydroepiandrosterone sulfotransferase pharmacogenetics: Quantitative Western analysis and gene sequence polymorphisms , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[101]  C. Mathew,et al.  Sequence variants of the estrogen receptor (ER) gene found in breast cancer patients with ER negative and progesterone receptor positive tumors. , 1996, Cancer letters.

[102]  B Fisher,et al.  Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. , 1996, Journal of the National Cancer Institute.

[103]  C. Mendelson,et al.  Tumor necrosis factor-alpha stimulates aromatase gene expression in human adipose stromal cells through use of an activating protein-1 binding site upstream of promoter 1.4. , 1996, Molecular endocrinology.

[104]  Rod J. Rohrich,et al.  Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. , 1996, The Journal of clinical endocrinology and metabolism.

[105]  R. Higgs,et al.  Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats. , 1996, The Journal of pharmacology and experimental therapeutics.

[106]  S. Wilczynski,et al.  Aromatase gene expression and its exon I usage in human breast tumors. Detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[107]  M. Poutanen,et al.  Expression and regulation of 17β-hydroxysteroid dehydrogenase type 1 , 1996 .

[108]  J. Fontecilla-Camps,et al.  The structure of a complex of human 17beta-hydroxysteroid dehydrogenase with estradiol and NADP+ identifies two principal targets for the design of inhibitors. , 1996, Structure.

[109]  R. Campbell,et al.  Crystal structure of human estrogenic 17β-hydroxysteroid dehydrogenase complexed with 17β-estradiol , 1996, Nature Structural Biology.

[110]  H. Bryant,et al.  Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[111]  S. Chandrasekhar,et al.  Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate. , 1996, Bone.

[112]  T. Penning,et al.  17β-Hydroxysteroid dehydrogenase: inhibitors and inhibitor design , 1996 .

[113]  F. Kikkawa,et al.  Effects of the mutations (Trp8 --> Arg and Ile15 --> Thr) in human luteinizing hormone (LH) beta-subunit on LH bioactivity in vitro and in vivo. , 1996, Endocrinology.

[114]  F. Speizer,et al.  Cohort studies of fat intake and the risk of breast cancer--a pooled analysis. , 1996, The New England journal of medicine.

[115]  M. Sporn,et al.  Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. , 1996, Journal of the National Cancer Institute.

[116]  Dwight C. Look,et al.  Stat1 Depends on Transcriptional Synergy with Sp1 (*) , 1995, The Journal of Biological Chemistry.

[117]  G. Stein,et al.  Sp1 trans-activation of cell cycle regulated promoters is selectively repressed by Sp3. , 1995, Biochemistry.

[118]  E. Simpson,et al.  Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. , 1995, The Journal of clinical endocrinology and metabolism.

[119]  J. Lehmann,et al.  A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation , 1995, Cell.

[120]  T. Tamaya,et al.  Expression of sex hormone-binding globulin mRNA in uterine leiomyoma, myometrium and endometrium of human subjects. , 1995, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[121]  R. Vihko,et al.  Coordination of transcription of the human 17 beta-hydroxysteroid dehydrogenase type 1 gene (EDH17B2) by a cell-specific enhancer and a silencer: identification of a retinoic acid response element. , 1995, Molecular endocrinology.

[122]  J Benichou,et al.  Proportion of breast cancer cases in the United States explained by well-established risk factors. , 1995, Journal of the National Cancer Institute.

[123]  A. Rauth,et al.  Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. , 1995, British Journal of Cancer.

[124]  P. Jones,et al.  Prevalence of an immunological LH β‐subunit variant in a UK population of healthy women and women with polycystic ovary syndrome , 1995, Clinical endocrinology.

[125]  M. Simon,et al.  Gotta have GATA , 1995, Nature Genetics.

[126]  J. Rommens,et al.  Generation of a transcription map at the HSD17B locus centromeric to BRCA1 at 17q21. , 1995, Genomics.

[127]  S. Bulun,et al.  Aromatase P450 Gene Expression in Human Adipose Tissue. ROLE OF A Jak/STAT PATHWAY IN REGULATION OF THE ADIPOSE-SPECIFIC PROMOTER (*) , 1995, The Journal of Biological Chemistry.

[128]  M. Camilo,et al.  Tamoxifen-associated steatohepatitis--report of three cases. , 1995, Journal of hepatology.

[129]  E. Garrett,et al.  Ovarian carcinoma-associated TaqI restriction fragment length polymorphism in intron G of the progesterone receptor gene is due to an Alu sequence insertion. , 1995, Cancer research.

[130]  E. Simpson,et al.  Ad4BP/SF-1 Regulates Cyclic AMP-induced Transcription from the Proximal Promoter (PII) of the Human Aromatase P450 (CYP19) Gene in the Ovary (*) , 1995, The Journal of Biological Chemistry.

[131]  M Krook,et al.  Short-chain dehydrogenases/reductases (SDR). , 1995, Biochemistry.

[132]  W. Pangborn,et al.  Structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase at 2.20 A resolution. , 1995, Structure.

[133]  I. Huhtaniemi,et al.  Occurrence and biological properties of a common genetic variant of luteinizing hormone. , 1995, The Journal of clinical endocrinology and metabolism.

[134]  N. Roodi,et al.  Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. , 1995, Journal of the National Cancer Institute.

[135]  M. Sato,et al.  Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats. , 1995, The Journal of pharmacology and experimental therapeutics.

[136]  C. Mendelson,et al.  Characterization of the sequences of the human CYP19 (aromatase) gene that mediate regulation by glucocorticoids in adipose stromal cells and fetal hepatocytes. , 1995, Molecular endocrinology.

[137]  N. Eberhardt,et al.  An Initiator Element Is Required for Maximal Human Chorionic Somatomammotropin Gene Promoter and Enhancer Function (*) , 1995, The Journal of Biological Chemistry.

[138]  J. Morissette,et al.  Mapping of the HSD17B2 gene encoding type II 17 beta-hydroxysteroid dehydrogenase close to D16S422 on chromosome 16q24.1-q24.2. , 1995, Genomics.

[139]  E. Cadenas,et al.  Antioxidant and prooxidant functions of DT-diaphorase in quinone metabolism. , 1995, Biochemical pharmacology.

[140]  S. Akman,et al.  NAD(P)H:quinone oxidoreductase expression and mitomycin C resistance developed by human colon cancer HCT 116 cells. , 1995, Cancer research.

[141]  A. Howell,et al.  Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer , 1995, The Lancet.

[142]  B. Franza,et al.  In vitro study of functional involvement of Sp1, NF-kappa B/Rel, and AP1 in phorbol 12-myristate 13-acetate-mediated HIV-1 long terminal repeat activation. , 1994, The Journal of biological chemistry.

[143]  T. Tamaya,et al.  Sex hormone-binding globulin mRNA levels in human uterine endometrium. , 1994, European journal of endocrinology.

[144]  R. Vihko,et al.  Regulation of 17 beta-hydroxysteroid dehydrogenase type 1 by epidermal growth factor and transforming growth factor-alpha in choriocarcinoma cells. , 1994, Endocrinology.

[145]  J. Richards.  Hormonal control of gene expression in the ovary. , 1994, Endocrine reviews.

[146]  M. Poutanen,et al.  Site-directed mutagenesis of the putative active site of human 17 beta-hydroxysteroid dehydrogenase type 1. , 1994, The Biochemical journal.

[147]  M. Poutanen,et al.  Hormonal regulation of rat 17 beta-hydroxysteroid dehydrogenase type 1 in cultured rat granulosa cells: effects of recombinant follicle-stimulating hormone, estrogens, androgens, and epidermal growth factor. , 1994, Endocrinology.

[148]  C. Turner,et al.  Raloxifene preserves bone strength and bone mass in ovariectomized rats. , 1994, Endocrinology.

[149]  J. D. Engel,et al.  GATA factor activity is required for the trophoblast-specific transcriptional regulation of the mouse placental lactogen I gene. , 1994, Development.

[150]  K. Korach,et al.  Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. , 1994, The New England journal of medicine.

[151]  M. Poutanen,et al.  Rat 17 beta-hydroxysteroid dehydrogenase type 1: primary structure and regulation of enzyme expression in rat ovary by diethylstilbestrol and gonadotropins in vivo. , 1994, Endocrinology.

[152]  O. Bernard,et al.  GATA-and SP1-binding sites are required for the full activity of the tissue-specific promoter of the tal-1 gene. , 1994, Oncogene.

[153]  B. Ponder,et al.  A point mutation in the putative TATA box, detected in nondiseased individuals and patients with hereditary breast cancer, decreases promoter activity of the 17 beta-hydroxysteroid dehydrogenase type 1 gene 2 (EDH17B2) in vitro. , 1994, Genomics.

[154]  T. Bourne,et al.  Effects of tamoxifen on uterus , 1994, The Lancet.

[155]  R. Vihko,et al.  Characterization of 17β-hydroxysteroid dehydrogenase type 1 in choriocarcinoma cells: regulation by basic fibroblast growth factor , 1994, Molecular and Cellular Endocrinology.

[156]  D. Ghosh,et al.  The refined three-dimensional structure of 3α,20β-hydroxysteroid dehydrogenase and possible roles of the residues conserved in short-chain dehydrogenases , 1994 .

[157]  L. Moore,et al.  3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats. , 1994, Journal of medicinal chemistry.

[158]  K. Parker,et al.  A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation , 1994, Cell.

[159]  C. Slemenda,et al.  Dual‐energy X‐ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[160]  N. Harada,et al.  Novel exon 1 of the aromatase gene specific for aromatase transcripts in human brain. , 1994, Biochemical and biophysical research communications.

[161]  S. Bulun,et al.  Competitive reverse transcription-polymerase chain reaction analysis indicates that levels of aromatase cytochrome P450 transcripts in adipose tissue of buttocks, thighs, and abdomen of women increase with advancing age. , 1994, The Journal of clinical endocrinology and metabolism.

[162]  Y. Nakamura,et al.  Allele loss on chromosome 16q24.2-qter occurs frequently in breast cancers irrespectively of differences in phenotype and extent of spread. , 1994, Cancer research.

[163]  K. Korach,et al.  Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[164]  N. Harada,et al.  Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[165]  E. Simpson,et al.  Exon-specific northern analysis and rapid amplification of cDNA ends (RACE) reveal that the proximal promoter II (PII) is responsible for aromatase cytochrome P 450 (CYP19) expression in human ovary , 1993, Molecular and Cellular Endocrinology.

[166]  D. Kelsell,et al.  Genetic analysis of the BRCA1 region in a large breast/ovarian family: refinement of the minimal region containing BRCA1. , 1993, Human molecular genetics.

[167]  C. Mendelson,et al.  Tissue-specific and hormonally controlled alternative promoters regulate aromatase cytochrome P450 gene expression in human adipose tissue. , 1993, The Journal of biological chemistry.

[168]  T. Orton,et al.  Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. , 1993, Cancer research.

[169]  J. Manson,et al.  Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study. , 1993, JAMA.

[170]  J. Simard,et al.  Detection of polymorphisms in the estradiol 17 beta-hydroxysteroid dehydrogenase II gene at the EDH17B2 locus on 17q11-q21. , 1993, Human molecular genetics.

[171]  K. Toda,et al.  Molecular cloning of a cDNA showing alternative splicing of the 5'-untranslated sequence of mRNA for human aromatase P-450. , 1993, European journal of biochemistry.

[172]  H. Hauner,et al.  Tumor necrosis factor-alpha prevents the differentiation of human adipocyte precursor cells and causes delipidation of newly developed fat cells. , 1993, The Journal of clinical endocrinology and metabolism.

[173]  G. Williams,et al.  The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. , 1993, Carcinogenesis.

[174]  M. Beato,et al.  Cloning by recognition site screening of two novel GT box binding proteins: a family of Sp1 related genes. , 1992, Nucleic acids research.

[175]  G. Hammond,et al.  Molecular analyses of a human sex hormone-binding globulin variant: evidence for an additional carbohydrate chain. , 1992, The Journal of clinical endocrinology and metabolism.

[176]  Sheng-Xiang Lin,et al.  Subunit identity of the dimeric 17 beta-hydroxysteroid dehydrogenase from human placenta. , 1992, The Journal of biological chemistry.

[177]  G. Aguiari,et al.  Dinucleotide repeat polymorphism in the human estrogen receptor (ESR) gene. , 1992, Human molecular genetics.

[178]  M. Parker,et al.  Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[179]  K. Danenberg,et al.  NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. , 1992, Cancer research.

[180]  M. Delgado-Rodríguez,et al.  Menopausal hormone replacement therapy and breast cancer: A meta‐analysis , 1992, Obstetrics and gynecology.

[181]  C. Mendelson,et al.  Tissue-specific promoters regulate aromatase cytochrome P450 gene expression in human ovary and fetal tissues. , 1991, Molecular endocrinology.

[182]  Y. Nakamura,et al.  Accumulation of genetic alterations and progression of primary breast cancer. , 1991, Cancer research.

[183]  V. Jordan,et al.  Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. , 1991, Journal of the National Cancer Institute.

[184]  F. Labrie,et al.  Localization of 17 beta-hydroxysteroid dehydrogenase throughout gestation in human placenta. , 1991, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[185]  K. Korach,et al.  The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. , 1991, Endocrinology.

[186]  C. Mendelson,et al.  Tissue-specific expression of human P-450AROM. The promoter responsible for expression in adipose tissue is different from that utilized in placenta. , 1991, The Journal of biological chemistry.

[187]  I. Kawashima,et al.  Molecular cloning of cDNA encoding adipogenesis inhibitory factor and identity with interleukin‐11 , 1991, FEBS letters.

[188]  G. Lavorgna,et al.  FTZ-F1, a steroid hormone receptor-like protein implicated in the activation of fushi tarazu , 1991, Science.

[189]  S. Thacker,et al.  A Meta-analysis of the Effect of Estrogen Replacement Therapy on the Risk of Breast Cancer , 1991 .

[190]  W. Isaacs,et al.  Allelic loss of chromosomes 16q and 10q in human prostate cancer. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[191]  T. Kawamoto,et al.  Structural and functional characterization of human aromatase P-450 gene. , 1990, European journal of biochemistry.

[192]  V. Jordan,et al.  Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. , 1990, Cancer research.

[193]  N. Harada,et al.  Structural characterization of the human estrogen synthetase (aromatase) gene. , 1990, Biochemical and biophysical research communications.

[194]  M. Gail,et al.  Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.

[195]  J. Mathis,et al.  Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen biosynthesis. , 1989, The Journal of biological chemistry.

[196]  V. Jordan,et al.  Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. , 1989, Cancer research.

[197]  T. Powles,et al.  A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. , 1989, British Journal of Cancer.

[198]  C. Redmond,et al.  A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. , 1989, The New England journal of medicine.

[199]  Nils Wilking,et al.  ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERS , 1989, The Lancet.

[200]  M. Badzioch,et al.  Combined effect of family history and reproductive factors on breast cancer risk , 1989, Cancer.

[201]  R. Vihko,et al.  Complete amino acid sequence of human placental 17β‐hydroxysteroid dehydrogenase deduced from cDNA , 1988, FEBS letters.

[202]  S. Lehrer,et al.  A variant estrogen receptor messenger ribonucleic acid is associated with reduced levels of estrogen binding in human mammary tumors. , 1988, Molecular endocrinology.

[203]  P. Cole,et al.  A Peroxide Model Reaction for Placental Aromatase. , 1988 .

[204]  M. Ghilchik,et al.  The effect of ethynyloestradiol and medroxyprogesterone acetate on the in vivo uptake and metabolism of 3H-oestradiol by breast tumour tissue in postmenopausal women. , 1987, Anticancer research.

[205]  W. Miller,et al.  Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): similarity with the gene for P450c21. , 1987, DNA.

[206]  C. Mendelson,et al.  Regulation by follicle-stimulating hormone of the synthesis of aromatase cytochrome P-450 in human granulosa cells. , 1987, Molecular endocrinology.

[207]  A. Wakeling,et al.  Steroidal pure antioestrogens. , 1987, The Journal of endocrinology.

[208]  C. Mendelson,et al.  Growth factors suppress and phorbol esters potentiate the action of dibutyryl adenosine 3',5'-monophosphate to stimulate aromatase activity of human adipose stromal cells. , 1986, Endocrinology.

[209]  J. Cuzick,et al.  THE PREVENTION OF BREAST CANCER , 1986, The Lancet.

[210]  J. Cuzick,et al.  TAMOXIFEN AND CONTRALATERAL BREAST CANCER , 1985, The Lancet.

[211]  A. V. Landeghem,et al.  Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. , 1985, Cancer research.

[212]  V. Jordan.  Biochemical pharmacology of antiestrogen action. , 1984, Pharmacological reviews.

[213]  C. Mendelson,et al.  Regulation of aromatase activity of cultured adipose stromal cells by catecholamines and adrenocorticotropin , 1984, Molecular and Cellular Endocrinology.

[214]  C. D. Jones,et al.  Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal in , 1984, Journal of medicinal chemistry.

[215]  V. Jordan,et al.  Differential antiestrogen action in the immature rat uterus: a comparison of hydroxylated antiestrogens with high affinity for the estrogen receptor. , 1983, Journal of steroid biochemistry.

[216]  V. Jordan,et al.  Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018. , 1983, Endocrinology.

[217]  Charles David Jones,et al.  Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. , 1983, Life sciences.

[218]  C. D. Jones,et al.  Antagonism of estrogen action with a new benzothiophene derived antiestrogen. , 1983, Life sciences.

[219]  S D Stellman,et al.  A different perspective on breast cancer risk factors: Some implications of the nonattributable risk , 1982, CA: a cancer journal for clinicians.

[220]  T. Thorsen,et al.  Concentration of endogenous oestradiol as related to oestradiol receptor sites in breast tumor cytosol. , 1982, European journal of cancer & clinical oncology.

[221]  M. Calder,et al.  Mechanistic studies on C-19 demethylation in oestrogen biosynthesis. , 1982, The Biochemical journal.

[222]  L. Black,et al.  Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY117018) in rats and mice. , 1980, Life sciences.

[223]  N. Ikekawa,et al.  The enzyme activity of bovine adrenocortical cytochrome P-450 producing pregnenolone from cholesterol: kinetic and electrophoretic studies on the reactivity of hydroxycholesterol intermediates. , 1978, Biochemical and biophysical research communications.

[224]  M. Gut,et al.  Intermediates in the conversion of cholesterol to pregnenolone: Kinetics and mechanism , 1976, Steroids.

[225]  M. Sporn.  Approaches to prevention of epithelial cancer during the preneoplastic period. , 1976, Cancer research.

[226]  M. Sporn,et al.  Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). , 1976, Federation proceedings.

[227]  Richard Doll,et al.  Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices , 1975, International journal of cancer.

[228]  G. S. Boyd,et al.  The cholesterol side-chain cleavage system of bovine adrenal cortex. , 1967, European journal of biochemistry.

[229]  U. Engelmann,et al.  The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. , 2001, The Journal of urology.

[230]  R. Herbst,et al.  Clinical studies of angiogenesis inhibitors: The university of texas md anderson center trial of human endostatin , 2001, Current oncology reports.

[231]  J. Cerhan,et al.  Sulfotransferase 1 A 1 Polymorphism , Endogenous Estrogen Exposure , Well-done Meat Intake , and Breast Cancer Risk 1 , 2001 .

[232]  D. Bentrem,et al.  Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen. , 2001, Endocrinology.

[233]  N. Sparano,et al.  Raloxifene hydrochloride. , 2000, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[234]  E. Simpson,et al.  Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. , 2000, Cancer research.

[235]  H. Melhus,et al.  Estrogen receptor alpha gene polymorphisms and endometrial cancer risk. , 2000, Carcinogenesis.

[236]  T. Visakorpi.  Molecular genetics of prostate cancer. , 1999, Annales chirurgiae et gynaecologiae.

[237]  D. Fowlkes,et al.  Comparative analyses of mechanistic differences among antiestrogens. , 1999, Endocrinology.

[238]  K. Matsumoto,et al.  Epithelial-cell-specific transcriptional regulation of human Galbeta1,3GalNAc/Galbeta1,4GlcNAc alpha2,3-sialyltransferase (hST3Gal IV) gene. , 1999, Biochemical and biophysical research communications.

[239]  H. Sasano,et al.  Oestrogen receptor alpha and beta mRNA expression in human endometrium throughout the menstrual cycle. , 1999, Molecular human reproduction.

[240]  R. Verma,et al.  Chromosomal basis of adenocarcinoma of the prostate. , 1999, Cancer investigation.

[241]  J. Rhim,et al.  Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[242]  T. Ishikawa,et al.  Matrilysin as a target for chemotherapy for colon cancer: use of antisense oligonucleotides as antimetastatic agents , 1999, Cancer Chemotherapy and Pharmacology.

[243]  R. Vihko,et al.  Identification of essential subelements in the hHSD17B1 enhancer: difference in function of the enhancer and that of the hHSD17BP1 analog is due to -480C and -486G. , 1999, Endocrinology.

[244]  K. Korach,et al.  Postnatal sex reversal of the ovaries in mice lacking estrogen receptors alpha and beta. , 1999, Science.

[245]  B. Katzenellenbogen,et al.  Transcriptional regulation of the human quinone reductase gene by antiestrogen-liganded estrogen receptor-alpha and estrogen receptor-beta. , 1998, The Journal of biological chemistry.

[246]  B. Bonanni,et al.  Prevention of breast cancer: focus on chemoprevention. , 1998, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[247]  N. Weigel,et al.  A Genetic Mutation in the Progesterone Receptor (PROGINS) leads to an increased risk of non-familial breast and ovarian cancer causing inadequate control of estrogen receptor driven proliferation , 1998 .

[248]  M. Pugeat,et al.  Human variant sex hormone-binding globulin (SHBG) with an additional carbohydrate chain has a reduced clearance rate in rabbit. , 1998, The Journal of clinical endocrinology and metabolism.

[249]  R. Jaffe,et al.  Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles. , 1998, The Journal of clinical endocrinology and metabolism.

[250]  C. Yang,et al.  Modulation of aromatase expression in the breast tissue by ERR alpha-1 orphan receptor. , 1998, Cancer research.

[251]  C. Labrie,et al.  Comparison of the effects of the antiestrogens EM-800 and tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice. , 1998, Cancer research.

[252]  I. Campbell,et al.  No association of a 306-bp insertion polymorphism in the progesterone receptor gene with ovarian and breast cancer. , 1997, British Journal of Cancer.

[253]  M. Poutanen,et al.  Characterization of structural and functional properties of human 17 beta-hydroxysteroid dehydrogenase type 1 using recombinant enzymes and site-directed mutagenesis. , 1997, Molecular endocrinology.

[254]  A. Børresen-Dale,et al.  Screening for ESR mutations in breast and ovarian cancer patients , 1997, Human mutation.

[255]  S. Bulun,et al.  Aromatase expression in health and disease. , 1997, Recent progress in hormone research.

[256]  D. Ross,et al.  Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). , 1997, British Journal of Cancer.

[257]  A. Jaiswal,et al.  Gene Expression of DT-Diaphorase in Cancer Cells , 1997 .

[258]  T. Powles,et al.  Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[259]  M. Poutanen,et al.  Expression of 17 beta-hydroxysteroid dehydrogenase in human granulosa cells: correlation with follicular size, cytochrome P450 aromatase activity and oestradiol production. , 1994, The Journal of endocrinology.

[260]  F. Kikkawa,et al.  Identification of two point mutations in the gene coding luteinizing hormone (LH) beta-subunit, associated with immunologically anomalous LH variants. , 1994, The Journal of clinical endocrinology and metabolism.

[261]  D. Williams,et al.  Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. , 1994, The Journal of clinical investigation.

[262]  T. Xie,et al.  NAD(P)H:quinone oxidoreductase1 (DT-diaphorase): expression, regulation, and role in cancer. , 1994, Oncology research.

[263]  I. Huhtaniemi,et al.  An immunologically anomalous luteinizing hormone variant in a healthy woman. , 1992, The Journal of clinical endocrinology and metabolism.

[264]  W D Dupont,et al.  Analysis of the PvuII restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood. , 1992, Cancer research.

[265]  R. Voutilainen,et al.  Regulation of aromatase cytochrome P-450 and 17 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels in choriocarcinoma cells. , 1992, Endocrinology.

[266]  T. Powles,et al.  Prevention of breast cancer with tamoxifen--an update on the Royal Marsden Hospital pilot programme. , 1990, European journal of cancer.

[267]  G. Hortobagyi,et al.  Phase II evaluation of Ly156758 in metastatic breast cancer. , 1988, Oncology.

[268]  T. Mohandas,et al.  Human aromatase: cDNA cloning, Southern blot analysis, and assignment of the gene to chromosome 15. , 1988, DNA.

[269]  Siiteri Pk.  Extraglandular oestrogen formation and serum binding of oestradiol: relationship to cancer. , 1981 .

[270]  G. Duvel.  The study group. , 1980 .

[271]  R. Hoover,et al.  Breast cancer risk factors among screening program participants. , 1979, Journal of the National Cancer Institute.

[272]  C. Labrie,et al.  Printed in U.S.A. Copyright © 1998 by The Endocrine Society Comparison of the Effects of the New Orally Active Antiestrogen EM-800 with ICI 182 780 and Toremifene on Estrogen-Sensitive Parameters in the Ovariectomized Mouse , 2022 .